PCYC â Ibrutinib One Step Closer To Market â FDA Accepts NDA for Ibrutinib In MCL and CLL/SLL and Grants Priority Review â Exactly 60 days after the filing (6/28), the FDA completed their review and determined that the application is sufficiently complete to permit a substantive review for both previously treated mantle cell lymphoma[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.